Gritstone Oncology is developing tumor-specific cancer immunotherapies to fight multiple cancer types. The lead product candidate, GRANITE, is a personalized neoantigen-based immunotherapy. The second product candidate, SLATE, is a shared neoantigen (âoff-the-shelfâ) immunotherapy. The company has developed its product candidates using two key pillarsâa proprietary machine learning-based platform, Gritstone EDGEâ˘, which provides a powerful ability to predict from a routine tumor biopsy the tumor-specific neoantigens, or TSNA, that are presented on a patientâs tumor cells; and second, the ability to develop and manufacture potent immunotherapies utilizing patientsâ TSNA to drive the patientâs immune system to attack and destroy tumors.
Source
